Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
Clinical Trials Arena on MSN
Gilead’s HIV single-pill combo meets primary endpoints in pivotal trial
Gilead has become a significant name in the HIV landscape after its twice-yearly PrEP treatment Yeztugo touted 99.9% efficacy ...
With a focus on Massachusetts, Rhode Island and Vermont, a project funded by the National Institute on Drug Abuse will ...
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread among ...
Despite highly effective HIV prevention drugs on the market, only a fraction of those at risk in the U.S. are taking them — or even know they're an option. It's called pre-exposure prophylaxis, or ...
The two-drug regimen dolutegravir/lamivudine is as effective as the three-drug regimen dolutegravir plus tenofovir ...
Gilead beats estimates, raises 2025 guidance, driven by strong HIV and liver drug sales and multiple launches planned for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback